Detalhe da pesquisa
1.
Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition.
Bioconjug Chem
; 33(5): 795-806, 2022 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35446024
2.
A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.
J Biol Chem
; 293(33): 12663-12680, 2018 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29934309
3.
Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers.
Mol Oncol
; 17(11): 2337-2355, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37609678
4.
A KLK4 proteinase substrate capture approach to antagonize PAR1.
Sci Rep
; 11(1): 16170, 2021 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34373558
5.
Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma.
Cancers (Basel)
; 13(16)2021 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34439122
6.
Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer.
J Med Chem
; 63(14): 7601-7615, 2020 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32442375
7.
Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.
J Med Chem
; 61(19): 8859-8874, 2018 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30212625
8.
Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model.
Cancer Biol Ther
; 16(11): 1682-8, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26192476